1. Home
  2. MCRB vs NYXH Comparison

MCRB vs NYXH Comparison

Compare MCRB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$9.03

Market Cap

139.7M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.02

Market Cap

190.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCRB
NYXH
Founded
2010
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
190.6M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
MCRB
NYXH
Price
$9.03
$4.02
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$14.33
$11.67
AVG Volume (30 Days)
100.7K
52.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
2.40
N/A
Revenue
$126,325,000.00
N/A
Revenue This Year
N/A
$97.32
Revenue Next Year
N/A
$241.74
P/E Ratio
$3.63
N/A
Revenue Growth
1672.24
N/A
52 Week Low
$0.36
$3.92
52 Week High
$29.98
$11.87

Technical Indicators

Market Signals
Indicator
MCRB
NYXH
Relative Strength Index (RSI) 32.83 37.16
Support Level $7.12 N/A
Resistance Level $16.14 $4.99
Average True Range (ATR) 0.96 0.31
MACD -0.01 -0.04
Stochastic Oscillator 16.03 8.37

Price Performance

Historical Comparison
MCRB
NYXH

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: